

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT INTENTION TO CONDUCT FURTHER ON-MARKET SHARE REPURCHASE

This announcement is made by Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, or “**we**”, or “**us**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company hereby announces that the Company will conduct on-market share repurchase of up to HK\$500 million in aggregate (including the shares of approximately HK\$5.36 million repurchased by the Company through The Stock Exchange of Hong Kong Limited (the “**Stock Exchange**”) in the first half of 2024) based on market conditions and capital arrangement within twelve months from the date of this announcement at the time and frequency determined by the Board from time to time. The Company will finance the share repurchase from its available cash reserves.

The share repurchase will be conducted in accordance with the restrictions of the general mandate to repurchase shares granted or to be granted to the Directors by the shareholders of the Company (the “**Shareholders**”) at annual general meetings (including the annual general meeting held on 7 June 2024), and subject to the bye-laws of the Company, the Rules Governing the Listing of Securities on the Stock Exchange, the Codes on Takeovers and Mergers and Share Buy-backs of Hong Kong and other applicable laws and regulations.

The Board believes that the implementation of the share repurchase is in the interests of the Company and its Shareholders as a whole. Sihuan Pharmaceutical has always been committed to achieving the strategic goal of becoming a leading medical aesthetics and biopharmaceutical enterprise in China. The Company has made several positive business progresses in its new businesses of medical aesthetics and innovative pharmaceuticals. The Company’s carefully incubated medical aesthetics platform, Meiyuan Space, has evolved into a leading medical aesthetic company in China. It is a comprehensive integrated platform encompassing research, production and marketing, with a pipeline of more than 60 medical aesthetic products, covering the needs of the whole life cycle of beauty lovers. Nearly 20 innovative drugs and diabetes biosimilar drug products independently researched and developed by the Company have been approved for marketing, which will provide a robust new momentum for the future revenue growth of the Company’s pharmaceutical business. We hold great confidence in the Company’s future development prospects.

ABOUT SIHUAN PHARMACEUTICAL

Founded in 2001 and listed on the Main Board of the Stock Exchange in 2010, Sihuan Pharmaceutical is an international medical aesthetics and biopharmaceutical company led by innovation, with an independent and leading R&D technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic objective of “full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses”, Sihuan Pharmaceutical endeavours to build itself into a leading medical aesthetics and biopharmaceutical company in China.

The share repurchase of the Company is subject to market conditions and will be made at the sole discretion of the Board. No guarantee is given as to the timing, amount or price of the shares to be repurchased. Shareholders and potential investors are advised to exercise caution when dealing in the securities of the Company.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 6 October 2024

As at the date of this announcement, the executive Directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive Directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.